Technical Analysis for SHPG - Shire plc

Grade Last Price % Change Price Change
grade F 140.85 -3.23% -4.70
SHPG closed down 3.23 percent on Monday, August 21, 2017, on 2.2 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical SHPG trend table...

Date Alert Name Type % Chg
Aug 21 New 52 Week Low Other 0.00%
Aug 21 New 52 Week Closing Low Bearish 0.00%
Aug 18 New 52 Week Low Other -3.23%
Aug 18 Hammer Candlestick Bullish -3.23%
Aug 18 New 52 Week Closing Low Bearish -3.23%

Older signals for SHPG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Is SHPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 209.22
52 Week Low 144.18
Average Volume 1,424,529
200-Day Moving Average 171.7411
50-Day Moving Average 162.3566
20-Day Moving Average 156.8405
10-Day Moving Average 148.758
Average True Range 3.4287
ADX 29.55
+DI 16.0
-DI: 47.29
Chandelier Exit (Long, 3 ATRs) 161.3039
Chandelier Exit (Short, 3 ATRs) 149.6461
Upper Bollinger Band 175.3582
Lower Bollinger Band 138.3228
Percent B (%b) 0.07
Bandwidth 0.236134
MACD Line -5.7515
MACD Signal Line -4.4651
MACD Histogram -1.2864